Detalhe da pesquisa
1.
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.
Blood
; 143(5): 404-416, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37890149
2.
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study.
J Clin Oncol
; 42(10): 1146-1157, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38072625
3.
Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma.
Blood Adv
; 5(8): 2245-2255, 2021 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33904895
4.
Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial.
Blood Adv
; 5(6): 1695-1705, 2021 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33720336
5.
Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist.
Transfusion
; 45(3): 295-300, 2005 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15752146